Evidence map›Paper›PMID 40916371›Full record

ArticleFuture oncology (London, England)2025

Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.

Bijal D Shah, Mei Xue, Wesley Furnback, Keri Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bijal D ShahDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Mei XueHEOR & RWE, Global Medical Affairs, BeOne Medicines Ltd, San Carlos, CA, USA.
Wesley FurnbackInsights & Evidence, Real Chemistry, Inc., New York, NY, USA.
Keri YangHEOR & RWE, Global Medical Affairs, BeOne Medicines Ltd, San Carlos, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study examines United States real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns, duration, and adherence in mantle cell lymphoma (MCL) patients. MATERIALS &

methodsA retrospective analysis of electronic medical records for patients with MCL who initiated a BTKi between January 2019 and November 2021 was conducted. Patients were followed ≥ 6 months, examining baseline characteristics and outcomes including treatment duration and adherence.

results402 patients initiated acalabrutinib (n = 161), ibrutinib (n = 197), or zanubrutinib (n = 44). The zanubrutinib group demonstrated significantly longer median treatment duration (292 days) compared with acalabrutinib (259 days) and ibrutinib (149 days;

conclusionsIn this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.

Indexed as

Agammaglobulinaemia Tyrosine KinaseLymphoma, Mantle-CellProtein Kinase InhibitorsAdenineAdultAgedAged, 80 and overBenzamidesFemaleHumansMaleMiddle AgedPiperidinesPyrazinesPyrazolesPyrimidinesacalabrutinibAdenineAgammaglobulinaemia Tyrosine KinaseBenzamidesBTK protein, humanibrutinibPiperidinesProtein Kinase InhibitorsPyrazinesPyrazolesPyrimidinesTyrosine Kinase InhibitorszanubrutinibadherenceBruton tyrosine kinase inhibitorBTKiMantle cell lymphomatreatment discontinuationtreatment duration

Identifiers

PMID40916371
PMCPMC12490371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.